BioVie (BIVI) 10-Q 11 Feb 25 2025 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Dec. 31, 2024	Feb. 07, 2025
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--06-30
Entity File Number	001-39015
Entity Registrant Name	BIOVIE INC.
Entity Central Index Key	0001580149
Entity Tax Identification Number	46-2510769
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	680 W Nye Lane
Entity Address, Address Line Two	Suite 204
Entity Address, City or Town	Carson City
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89703
City Area Code	775
Local Phone Number	888-3162
Title of 12(b) Security	Class A Common Stock, $0.0001 par value per share
Trading Symbol	BIVI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,451,981

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
CURRENT ASSETS:
Cash and cash equivalents	$ 24,405,517	$ 23,843,798
Prepaid and other current assets	275,835	204,392
Total current assets	24,681,352	24,048,190
Operating lease right-of-use asset, net	374,303	406,726
Intangible assets, net	293,030	407,718
Goodwill	345,711	345,711
TOTAL ASSETS	25,694,396	25,208,345
CURRENT LIABILITIES:
Accounts payable and accrued expenses	1,382,501	3,586,912
Current portion of operating lease liability	67,111	60,343
Current portion of notes payable, net of financing cost, unearned premium and discount of $701,210 at June 30, 2024		5,701,210
Warrant liability	7,290	3,771
Total current liabilities	1,456,902	9,352,236
Operating lease liability, net of current portion	314,915	349,894
TOTAL LIABILITIES	1,771,817	9,702,130
STOCKHOLDERS' EQUITY :
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 800,000,000 shares authorized at December 31, 2024 and June 30, 2024; 18,478,307 shares issued of which 18,451,981 shares are outstanding at December 31, 2024; and 6,216,398 shares issued of which 6,190,072 shares outstanding at June 30, 2024	7,456	6,229
Additional paid in capital	369,781,837	349,732,674
Accumulated deficit	(345,866,687)	(334,232,661)
Treasury stock	(27)	(27)
Total stockholders' equity	23,922,579	15,506,215
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 25,694,396	$ 25,208,345

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Statement of Financial Position [Abstract]
Unearned premium and discount current		$ 701,210
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	800,000,000	800,000,000
Common stock, shares issued	18,478,307	6,216,398
Common stock, shares outstanding	18,451,981	6,190,072

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
OPERATING EXPENSES:
Amortization of intangible assets	$ 57,344	$ 57,344	$ 114,688	$ 114,688
Research and development expenses	4,704,806	6,470,262	6,695,003	15,345,922
Selling, general and administrative expenses	2,530,679	2,253,802	4,605,219	4,196,619
TOTAL OPERATING EXPENSES	7,292,829	8,781,408	11,414,910	19,657,229
LOSS FROM OPERATIONS	(7,292,829)	(8,781,408)	(11,414,910)	(19,657,229)
OTHER EXPENSE (INCOME):
Change in fair value of derivative liabilities	6,036	(982,534)	3,519	(1,690,336)
Interest expense	66,700	820,600	322,725	1,825,268
Interest income	(253,036)	(218,029)	(476,593)	(680,252)
TOTAL OTHER INCOME, NET	(180,300)	(379,963)	(150,349)	(545,320)
NET LOSS	(7,112,529)	(8,401,445)	(11,264,561)	(19,111,909)
Deemed dividend related to ratchet adjustment to warrants	44,424		369,465
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (7,156,953)	$ (8,401,445)	$ (11,634,026)	$ (19,111,909)
NET LOSS PER COMMON SHARE
- Basic	$ (0.46)	$ (2.20)	$ (1.05)	$ (5.10)
- Diluted	$ (0.46)	$ (2.20)	$ (1.05)	$ (5.10)
WEIGHTED AVERAGE NUMBER OF COMMON  SHARES OUTSTANDING
- Basic	15,717,247	3,817,077	11,042,832	3,744,476
- Diluted	15,717,247	3,817,077	11,042,832	3,744,476
Other comprehensive loss
Reclassification of unrealized gains on available-for-sale investments upon settlement				$ (176,591)
Total other comprehensive loss				(176,591)
Comprehensive loss	$ (7,156,953)	$ (8,401,445)	$ (11,634,026)	$ (19,288,500)

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stocks [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jun. 30, 2023	$ 3,643	$ 316,385,759	$ (2)	$ 176,591	$ (301,225,705)	$ 15,340,286
Beginning balance, shares at Jun. 30, 2023	3,645,183		(2,288)
Stock-based compensation - stock options		808,027				808,027
Stock-based compensation - restricted stock units		380,834				380,834
Proceeds from issuance of common stock, net of costs of $2,492,880	$ 4	1,905,832				1,905,836
Proceeds from issuance of common stock, net of costs, shares	43,220
Issuance of common stock from vesting of - restricted stock units
Issuance of common stock from vesting of - restricted stock units, shares	3,873
Net Loss					(10,710,464)	(10,710,464)
Relcassification of unrealized gains on available for sale investments upon settlement				(176,591)		(176,591)
Ending balance, value at Sep. 30, 2023	$ 3,647	319,480,452	$ (2)		(311,936,169)	7,547,928
Ending balance, shares at Sep. 30, 2023	3,692,276		(2,288)
Stock-based compensation - stock options		619,701				619,701
Stock-based compensation - restricted stock units		303,173				303,173
Proceeds from issuance of common stock, net of costs of $2,492,880	$ 290	7,421,588				7,421,878
Proceeds from issuance of common stock, net of costs, shares	290,090
Issuance of common stock from vesting of - restricted stock units	$ 4	(4)
Issuance of common stock from vesting of - restricted stock units, shares	4,305
Net Loss					(8,401,445)	(8,401,445)
Ending balance, value at Dec. 31, 2023	$ 3,941	327,824,910	$ (2)		(320,337,614)	7,491,235
Ending balance, shares at Dec. 31, 2023	3,986,671		(2,288)
Beginning balance, value at Jun. 30, 2024	$ 6,229	349,732,674	$ (27)		(334,232,661)	15,506,215
Beginning balance, shares at Jun. 30, 2024	6,216,398		(26,326)
Stock-based compensation - stock options		118,898				118,898
Stock-based compensation - restricted stock units		301,491				301,491
Proceeds from issuance of common stock, net of costs of $2,492,880	$ 163	2,258,900				2,259,063
Proceeds from issuance of common stock, net of costs, shares	1,627,943
Issuance of additional shares for fractional shares effected by the reverse split	$ 12	(12)
Issuance of additional shares for fractional shares effected by the reverse split, shares	120,237
Deemed dividend for ratchet adjustment to warrants		325,041			(325,041)
Issuance of common stock from vesting of - restricted stock units
Issuance of common stock from vesting of - restricted stock units, shares	3,408
Stock-based compensation - issuance of common stock for services rendered	$ 2	33,448				33,450
Stock-based compensation - issuance of common stock for services rendered, shares	15,000
Net Loss					(4,152,032)	(4,152,032)
Ending balance, value at Sep. 30, 2024	$ 6,406	352,770,440	$ (27)		(338,709,734)	14,067,085
Ending balance, shares at Sep. 30, 2024	7,982,986		(26,326)
Stock-based compensation - stock options		385,328				385,328
Stock-based compensation - restricted stock units		265,804				265,804
Proceeds from issuance of common stock, net of costs of $2,492,880	$ 826	13,414,724				13,415,550
Proceeds from issuance of common stock, net of costs, shares	8,256,000
Deemed dividend for ratchet adjustment to warrants		44,424			(44,424)
Issuance of common stock from vesting of - restricted stock units
Issuance of common stock from vesting of - restricted stock units, shares	3,807
Exercise of warrants	$ 224	2,901,117				2,901,341
Exercise of warrants, shares	2,231,300
Cashless exercise of warrants
Cashless exercise of warrants, shares	4,214
Net Loss					(7,112,529)	(7,112,529)
Ending balance, value at Dec. 31, 2024	$ 7,456	$ 369,781,837	$ (27)		$ (345,866,687)	$ 23,922,579
Ending balance, shares at Dec. 31, 2024	18,478,307		(26,326)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (11,264,561)	$ (19,111,909)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of intangible assets	114,688	114,688
Stock based compensation - restricted stock units	567,295	684,007
Stock based compensation expense - stock options	504,226	1,427,728
Stock based compensation expense - issuance of common stock for services rendered	33,450
Amortization of financing costs	11,820	68,560
Accretion of unearned loan discount	111,212	645,027
Accretion of loan premium	25,758	149,394
Realized gain on maturity of available-for sale		(223,865)
Non-cash lease expense from right-of-use assets	32,423	20,371
Change in fair value of derivative liabilities	3,519	(1,690,336)
Changes in operating assets and liabilities:
Prepaid and other current assets	(71,443)	(232,437)
Accounts payable and accrued expenses	(2,204,411)	131,837
Operating lease liabilities	(28,211)	(21,579)
Other current liabilities		(48,385)
Net cash used in operating activities	(12,164,235)	(18,086,899)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from U.S. Treasury Bills (available-for-sale)		14,525,000
Net cash provided by investing activities		14,525,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock	15,674,613	9,327,714
Proceeds from exercise of warrants	2,901,341
Payment of loan premium	(850,000)
Payments of note payable	(5,000,000)	(5,000,000)
Net cash provided by financing activities	12,725,954	4,327,714
Net change in cash and cash equivalents	561,719	765,815
Cash and cash equivalents, beginning of period	23,843,798	19,460,883
Cash and cash equivalents, end of period	24,405,517	20,226,698
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	173,935	962,288
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES:
Reclassification of unrealized gains on U.S. Treasury Bills (available-for-sale investments) upon settlement		176,591
Deemed dividend for ratchet adjustment to warrants	$ 369,465

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (7,112,529)	$ (4,152,032)	$ (8,401,445)	$ (10,710,464)

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Dec. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Background Information

Background Information	6 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background Information	1. Background Information BioVie Inc. (the “Company” or “we” or “our”) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease. The Company acquired the biopharmaceutical assets of NeurMedix, Inc. (“NeurMedix”) a privately held clinical-stage pharmaceutical company and a related party in June 2021 . Neurodengenerative Disease Program In neurodegenerative disease, the Company’s drug candidate Bezisterim (NE3107) inhibits activation of inflammatory actions extracellular single-regulated kinase (“ERK”) and nuclear factor kappa-light-chain-enhancer of activated B cells (“NFκB”) (including interactions with tumor necrosis factor (“TNF”) signaling and other relevant inflammatory pathways) that lead to neuroinflammation and insulin resistance. NE3107 does not interfere with their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of AD and PD. Alzheimer’s Disease On November 29, 2023, the Company announced the analysis of its unblinded, topline efficacy data from its Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate AD. The study has co-primary endpoints looking at cognition using the Alzheimer’s Disease Assessment Scale-Cognitive Scale (ADAS-Cog 12) and function using the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Patients were randomly assigned, 1:1 versus placebo, to receive sequentially 5 mg of NE3107 orally twice a day for 14 days, then 10 mg orally twice a day for 14 days, followed by 26 weeks of 20 mg orally twice daily. Upon trial completion, as the Company began the process of unblinding the trial data, the Company found significant deviation from protocol and current good clinical practices (“cGCPs”) violations at 15 study sites (virtually all of which were from one geographic area). This highly unusual level of suspected improprieties led the Company to exclude all patients from these sites and to refer the sites to the FDA Office of Scientific Investigations (“OSI”) for potential further action. After the patient exclusions, 81 patients remained in the Modified Intent to Treat population, 57 of whom were in the Per-Protocol population which included those who completed the trial and were verified to take study drug from pharmacokinetic data. The trial was originally designed to be 80% powered with 125 patients in each of the treatment and placebo arms. The unplanned exclusion of so many patients left the trial underpowered for the primary endpoints. In the Per-Protocol population, which included those patients who completed the trial and who were further verified to have taken the study drug (based on pharmacokinetic data), an observed descriptive change from baseline appeared to suggest a slowing of cognitive loss; these same patients experienced an advantage in age deceleration vs. placebo as measured by DNA epigenetic change. Age deceleration is used by longevity researchers to measure the difference between the patient’s biological age, in this case as measured by the Horvath DNA methylation Skin Blood Clock, relative to the patient’s actual chronological age. This test was a non-primary/secondary endpoint, other-outcome measure, done via blood test collected at week 30 (end of study). Additional DNA methylation data continues to be collected and analyzed. Parkinson’s Disease The Phase 2 study of bezisterim (NE3107) for the treatment of PD (NCT05083260), completed in December 2022, was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in PD participants treated with carbidopa/levodopa and bezisterim (NE3107). Forty-five patients with a defined L-dopa “off state” were randomized 1:1 to placebo: bezisterim (NE3107) 20 mg twice daily for 28 days. This trial was launched with two design objectives: 1) the primary objective was safety and a drug-drug interaction study as requested by the FDA to measure the potential for adverse interactions of bezisterim (NE3107) with carbidopa/ levodopa; and 2) the secondary objective was to determine if preclinical indications of promotoric activity and apparent enhancement of levodopa activity could be seen in humans. Both objectives were met. To extend this Phase 2 data in progressed patients, the Company has designed a new Phase 2 study of bezisterim (NE3107) as a potential first line therapy to treat patients with new onset PD. In July 2024, the Company submitted the new protocol and received a response from the FDA which permitted the Company to proceed with the study. The trial is anticipated to commence during the first calendar quarter of 2025. Long COVID Program In April 2024, the Company announced the grant of a clinical trial award of up to $13.1 million from the U.S. Department of Defense (“DOD”), awarded through the Peer Reviewed Medical Research Program of the Congressionally Directed Medical Research Programs. In August 2024, U.S. Army Medical Research and Development Command, Office of Human Research Oversight (“OHRO”) approved the Company’s plan to evaluate bezisterim (NE3107) for the treatment of neurological symptoms that are associated with long COVID. and the FDA authorized our Investigational New Drug (“IND”) application for bezisterim (NE3107) allowing the Company to study a novel, anti-inflammatory approach or the treatment of the debilitating neurocognitive symptoms associated with long covid. The Company anticipates the trial to commence by first calendar quarter of 2025. The Company was reimbursed approximately $325,000 for trial costs during the six months ended December 31, 2024. Subsequent to December 31, 2024, additional reimbursements of approximately $2.6 million were received for trial costs incurred through December 31, 2024. Liver Disease Program In liver disease, our investigational drug candidate BIV201 (continuous infusion terlipressin), which has been granted both FDA Fast Track designation status and FDA Orphan Drug status, is being evaluated and discussed after receiving guidance from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation. In June 2021, the Company initiated a Phase 2 study (NCT04112199) designed to evaluate the efficacy of BIV201 (terlipressin, administered by continuous infusion for two 28-day treatment cycles) combined with standard-of-care (“SOC”), compared to SOC alone, for the treatment of refractory ascites. The primary endpoints of the study are the incidence of ascites-related complications and change in ascites fluid accumulation during treatment compared to a pre-treatment period. In March 2023, the Company announced enrollment was paused and that data from the first 15 patients treated with BIV201 plus SOC appeared to show at least a 30% reduction in ascites fluid during the 28 days after treatment initiation compared to the 28 days prior to treatment. The change in ascites volume was significantly different from those patients receiving SOC treatment. Patients who completed the treatment with BIV201 experienced a 53% reduction in ascites fluid, which was sustained (43% reduction) during the three months after treatment initiation as compared to the three-month pre-treatment period. In June 2023, the Company requested and subsequently received guidance from the FDA regarding the design and endpoints for definitive clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The Company is currently finalizing protocol designs for the Phase 3 study of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The BIV201 development program was initiated by LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to this drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.

Liquidity and Going Concern

Liquidity and Going Concern	6 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products; the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2024, the Company had working capital of approximately $ 23.2 24.4 23.9 345.9 The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue the Company’s strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Basis of Presentation – Interim Financial Information These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2024, was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2024 and 2023 in our Annual Report on Form 10-K filed with the SEC on September 30, 2024 (the “2024 Form 10-K”). A summary of significant accounting policies can also be found in those audited financial statements in the 2024 Form 10-K. Cash and cash equivalents Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of three months or less. Investments in U.S. Treasury Bills Investments in U.S. Treasury Bills with maturities greater than three months, are accounted for as available-for-sale and are recorded at fair value. Realized gains were included in the accompanying condensed statements of operations and comprehensive loss from the settlement of available-for-sale investments during the six months ended December 31, 2023. The Company had no outstanding investment securities with original maturities of greater than three months at the time of purchase as of and during the three and six months ended December 31, 2024. Concentration of Credit Risk in the Financial Service Industry As of December 31, 2024, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, if liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations. Fair value measurement of assets and liabilities We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 - Inputs are unobservable inputs based on our assumptions. The Company’s financial instruments include cash and cash equivalents, accounts payable and the carrying value of the operating lease liabilities and notes payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments. Net Loss per Common Share Basic net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding and potentially outstanding shares of Common Stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the three and six months ending December 31, 2024 and 2023, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the periods presented. The table below shows the potential shares of common stock, presented based on amounts outstanding at each period end, which were excluded from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: Schedule of dilutive securities were excluded from the computation of diluted loss per share December 31, 2024 December 31, 2023 Number of Shares Number of Shares Stock Options 967,811 471,333 Warrants 9,600,835 777,029 Restricted Stock Units 97,067 68,743 Notes payable conversion option - 71,633 Total 10,665,713 1,388,738 Reverse stock split The company effected a 1:10 reverse split of the issued and outstanding shares of its Class A common stock which was approved by the board of directors after the approval obtained from shareholders at a special meeting on July 29, 2024 which became effective on Nasdaq on August 6, 2024, 5 trading days after the shareholders’ approval was obtained. All historical share and earnings per share amounts have been retroactively adjusted to reflect the split. Grant program The Company records expenses related to the DOD Long Covid Program as such expenses are incurred. The reimbursement of such expenses is recognized upon receipt of the reimbursement as a credit against the respective expense account. Recent Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (“DISE”), which will require additional disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The new standard will be effective for public companies for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company is currently evaluating the impact of this accounting standard update on its financial statements.

Intangible Assets

Intangible Assets	6 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	4. Intangible Assets The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the Company’s intangible assets: Schedule of intangible assets December 31, 2024 June 30, 2024 Intellectual Property $ 2,293,770 $ 2,293,770 Less: Accumulated Amortization (2,000,740 ) (1,886,052 ) Intellectual Property, Net $ 293,030 $ 407,718 Amortization expense was $ 57,344 114,688 10 Estimated future amortization expense is as follows: Schedule of future amortization expense Year ending June 30, 2025 (Remaining 6 months) $ 114,689 2026 178,341 $ 293,030

Related Party Transactions

Related Party Transactions	6 Months Ended
	Dec. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	5. Related Party Transactions Equity Transactions with Acuitas On July 15, 2022, the Company entered into a securities purchase agreement with Acuitas Group Holdings, LLC (“Acuitas”), the Company’s largest stockholder, pursuant to which Acuitas agreed to purchase from the Company, in a private placement, (i) an aggregate of 363,636 For the three months ended September 30, 2024, the Company calculated the difference in fair value of the PIPE Warrant Shares between the stated exercise price and the reduced exercise price and recorded $ 325,041 1.20 1.53 10.00 2.9 3.5% 93.0% For the three months ended December 31, 2024, the Company calculated the difference in fair value of the PIPE Warrant Shares between the stated exercise price and the reduced exercise price and recorded $ 44,424 3.36 1.53 1.37 2.8 3.99% 94.0% For the six months ended December 31, 2024, the Company recorded $ 369,465 Consulting expenses During the three months ended December 31, 2024, the Company paid a Director of the Company $ 50,000

Notes Payable

Notes Payable	6 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable On November 30, 2021 (the “Closing Date”), the Company entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement and Promissory Notes (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. (“AVOPI”) and Avenue Venture Opportunities Fund II, L.P. (“AVOPII,” and together with AVOPI, “Avenue”) for growth capital loans in an aggregate commitment amount of up to $20 million (the “Loan”). On the Closing Date, $15 million of the Loan was funded (“Tranche 1”). The Loan bore interest at an annual rate equal to the greater of (a) the sum of 7.00% 4.25% The Loan Agreement included a conversion option to convert up to $5.0 million of the principal amount of the Loan outstanding at the option of Avenue, into shares of the Company’s Common Stock at a conversion price of $69.80 per share (the “Conversion Option”). On the Closing Date, the Company also issued to Avenue warrants to purchase 36,101 shares of Common Stock of the Company (the “Avenue Warrants”) at an exercise price per share equal to $58.20. The Avenue Warrants are exercisable until November 30, 2026. The amount of the carrying value of the notes payable was determined by allocating portions of the outstanding principal of the notes, resulting in approximately $ 1.4 2.2 390,000 850,000 Total interest expense associated with the Loan was approximately $ 62,000 33,000 2,000 22,000 5,000 312,000 163,000 12,000 111,000 26,000 Total interest expense associated with the Loan for the three months ended December 31, 2023 was approximately $ 682,000 429,000 31,000 289,000 67,000 1.5 955,000 69,000 645,000 149,000 The following is a summary of the Notes Payable as of December 31, 2024 and June 30, 2024: Schedule of note payable December 31, 2024 June 30, 2024 Current portion of Notes Payable $ - $ 5,000,000 Less: debt financing costs - (11,820 ) Less: unearned discount - (111,212 ) Plus: accretion of Loan Premium - 824,242 Current portion of Notes Payable, net of financing costs, unearned premium and discount $ - $ 5,701,210

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	7. Fair Value Measurements At December 31, 2024 and June 30, 2024, the estimated fair value of derivative liabilities measured on a recurring basis are as follows: Schedule of derivative liabilities at fair value Fair Value Measurements at December 31, 2024 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ - $ - $ 7,290 $ 7,290 Derivative liability - Conversion Option - - - - Total derivative liabilities $ - $ - $ 7,290 $ 7,290 Fair Value Measurements at June 30, 2024 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ - $ - $ 3,771 $ 3,771 Derivative liability - Conversion option - - - - Total derivative liabilities $ - $ - $ 3,771 $ 3,771 The following table presents the activity for level 3 liabilities measured at fair value using unobservable inputs for the six months ended December 31, 2024: Fair value, liabilities measured on recurring basis Derivative liabilities - Derivative liability - Balance at June 30, 2024 $ 3,771 $ - Additions to level 3 liabilities - - Change in fair value of level 3 liabilities 3,519 - Transfer in and/or out of Level 3 - - Balance at December 31, 2024 $ 7,290 $ - The following table presents the activity for level 3 liabilities measured at fair value using unobservable inputs for the six months ended December 31, 2023: Derivative liability - Derivative liability - Balance at June 30, 2023 $ 894,280 $ 925,762 Additions to level 3 liabilities - - Change in fair value of level 3 liabilities (771,122 ) (919,214 ) Transfer in and/or out of level 3 - - Balance at December 31, 2023 $ 123,158 $ 6,548 The fair value of the Avenue Warrants at December 31, 2024, in the accompanying condensed balance sheets, was $ 7,290 3,519 1.7 2.00 58.20 1.9 4.2% 95.0% Derivative liability – Avenue Warrants The Avenue Warrants were not considered to be indexed to the Company’s own stock, and accordingly, were recorded as a derivative liability at fair value in the accompanying condensed balance sheets at December 31, 2024 and June 30, 2024, respectively. The Black Scholes model was used to calculate the fair value of the derivative warrant to bifurcate the amount from the Avenue Loan amount funded. The Avenue Warrants are recorded at fair value at the date of issuance and remeasured at each subsequent reporting period end date. Embedded derivative liability – Conversion Option The Conversion Option was accounted for as an embedded derivative liability and required bifurcation from the Loan amount. The Black Scholes model was used to calculate the fair value of the Conversion Option to bifurcate it from the Loan. Financial assets As of December 31, 2024, investments in U.S. Treasury Bills were valued through use of quoted prices and are classified as Level 1. The following table presents information about our assets that are measured at fair value on a recurring basis using the above input categories. Measured at fair value on a recurring basis Fair Value Measurements at December 31, 2024 Level 1 Level 2 Level 3 Total Cash $ 4,326,075 $ - $ - $ 4,326,075 U.S. Treasury Bills due in 3 months or less at purchase 20,079,442 - - 20,079,442 Total $ 24,405,517 $ - $ - $ 24,405,517 Fair Value Measurements at June 30, 2024 Level 1 Level 2 Level 3 Total Cash $ 12,763,941 $ - $ - $ 12,763,941 U.S. Treasury Bills due in 3 months or less at purchase 11,079,857 - - 11,079,857 Total $ 23,843,798 $ - $ - $ 23,843,798

Equity Transactions

Equity Transactions	6 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Equity Transactions	8. Equity Transactions Issuance of common stock for cash On August 31, 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (collectively, the “Agents”), pursuant to which the Company may issue and sell from time-to-time shares of the Company’s common stock through the Agents, subject to the terms and conditions of the Sales Agreement. On April 6, 2023, the Company and B. Riley Securities, Inc. mutually agreed to terminate B. Riley Securities, Inc.’s role as a sales agent under the Sales Agreement. During the three months ended December 31, 2023, the Company sold 290,090 7.4 3% 258,000 333,310 9.3 3% 377,000 2,143 6,400 3% 200 On September 25, 2024, the Company closed a best efforts public offering (the “September 2024 Offering”) of 1,360,800 0.0001 600,000 1,960,800 1.53 The September Common Warrants have an exercise price of $ 1.53 3.0 98,040 125% In October 2024, the Company closed three registered direct offerings totaling 8,256,000 0.0001 7,110,000 1.50 2.83 . The October Common Warrants have exercise prices ranging from $ 1.37 2.12 15.9 2.5 1.88 3.54 During the three months ended December 31, 2024, 1,896,300 1.53 2.9 335,000 6,667 4,214 Issuance of common stock for services On August 12, 2024, the Company awarded 15,000 2.23 33,450 Stock Options The following table summarizes the activity relating to the Company’s stock options for the six months ended December 31, 2024: Schedule of summarizes the activity relating to the Company’s stock options Options Weighted-Average Weighted Remaining Aggregate Intrinsic Outstanding at June 30, 2024 518,076 $ 54.11 6.1 $ - Options Granted 490,261 2.40 7.1 - Options Expired (31,736 ) 71.34 - - Options Canceled (8,790 ) 17.01 - - Outstanding at December 31, 2024 967,811 $ 27.69 6.4 $ 32,196 Exercisable at December 31, 2024 409,987 $ 48.46 5.6 $ 10,732 The fair value of each option on the date of grant is estimated using the Black-Scholes option pricing model. The pricing model reflects the following weighted-average assumptions for the six months ended December 31, 2024 and 2023: Schedule of assumptions used December 31, 2024 December 31, 2023 Expected life of options (in years) 4 5 Expected volatility 93.44% 87.11% Risk free interest rate 4.34% 4.80% Dividend Yield 0% 0% On December 20, 2024, the Company issued to employees and directors stock options to purchase 208,902 113,055 1.90 1.20 1.43 The Company recorded stock-based compensation expense relating to the vesting of stock options of approximately $ 385,000 620,000 504,000 1.4 Restricted stock units: On November 20, 2024, the Company issued equity awards as part of the board of directors’ annual compensation. Two directors received 66,900 3.36 168,300 3.36 3,410 Additionally, during the three months ended December 31, 2024, 397 The following table summarizes the unvested restricted stock units outstanding at June 30, 2024 and December 31, 2024: Schedule of unvested of restricted stock units Number of Shares Weighted Average Grant Unvested at June 30, 2024 40,291 $ 44.59 Issued 66,900 3.36 Vested (15,291 ) 47.33 Canceled (2,913 ) 36.45 Unvested at December 31, 2024 88,987 $ 13.41 The total stock-based compensation expense from restricted stock units for the three months ended December 31, 2024 and 2023 was approximately $ 266,000 303,000 567,000 684,000 There were 8,080 Stock Warrants The following table summarizes the warrants activity during the six months ended December 31, 2024: Summary of warrants activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Life Aggregate Intrinsic Value Outstanding and exercisable at June 30, 2024 1,932,029 $ 14.03 4.0 $ - Granted 10,181,640 1.65 4.8 - Exercised (2,502,967 ) 1.53 - - Expired (9,867 ) 22.50 - - Outstanding and exercisable at December 31, 2024 9,600,835 $ 3.50 4.6 $ 3,322,376 The table below shows the expiration of the warrants outstanding as of December 31, 2024: Schedule of warrants outstanding Number of Warrants Expiring June 30, 2025 271 2026 3,518 2027 36,100 2028 727,273 2029 1,155,000 2030 7,678,673 Total outstanding warrants 9,600,835

Leases

Leases	6 Months Ended
	Dec. 31, 2024
Leases
Leases	9. Leases Office Leases The Company pays an annual rent of $ 2,200 1 The Company’s San Diego office lease at 5090 Shoreham Place Suite 212, San Diego, CA 92122 commenced in February 2024. The current monthly base rate for the office space is $ 9,685 60 Total operating lease expense for the three months ended December 31, 2024 and 2023 was approximately $ 32,000 13,000 63,000 26,000 The right-of-use asset, net and current and non-current portion of the operating lease liabilities included in the accompanying condensed balance sheets are as follows: Schedule of deferred tax assets December 31, 2024 June 30, 2024 Assets Operating lease right-of-use asset, net $ 374,303 $ 406,726 Liabilities Current portion of operating lease liability $ 67,111 $ 60,343 Operating lease liability, net of current portion 314,915 349,894 Total operating lease liability $ 382,026 $ 410,237 At December 31, 2024, the future estimated minimum lease payments under non-cancelable operating leases are as follows: Schedule of future estimated minimum lease payments under non-cancelable operating leases Year ending June 30, 2025 (Remaining 6 months) $ 59,805 2026 122,042 2027 126,313 2028 130,734 2029 77,796 Total minimum lease payments 516,690 Less amount representing interest (134,664 ) Present value of future minimum lease payments 382,026 Less current portion of operating lease liability (67,111 ) Operating lease liability, net of current portion $ 314,915 Total cash paid for amounts included in the measurement of lease liabilities were $ 58,110 25,800 The weighted average remaining lease term and discount rate as of December 31, 2024 and June 30, 2024 were as follows: Schedule of weighted average remaining lease term and discount rate December 31, 2024 June 30, 2024 Weighted average remaining lease term (Years) Operating lease 4.1 4.6 Weighted average discount rate Operating lease 15.00 % 15.00 %

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Royalty Agreements Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, by and between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared by the members of LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc. Pursuant to the Technology Transfer Agreement entered into on July 25, 2016, by and between the Company and the University of Padova (Italy), the Company is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances, capped at a maximum of $200,000 per year. Shareholder class action complaint On January 19, 2024, a purported shareholder class action complaint, captioned Eric Olmstead v. BioVie Inc. et al. Way v. BioVie Inc. et al. In re BioVie Inc. Securities Litigation in violation of Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 promulgated thereunder. The class action is on behalf of purchasers of the Company’s securities during the period from December 7, 2022 through November 28, 2023, and seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney’s fees. The defendants filed a motion to dismiss the amended complaint on August 21, 2024, and plaintiffs filed their opposition on October 21, 2024 and the defendants’ reply brief was filed on December 5, 2024. On December 30, 2024, a shareholder derivative lawsuit was filed in the United States District Court for the District of Nevada by putative stockholder Andrew Hulm, allegedly on behalf of the Company, that piggy-backs on the securities class action also pending in that court. The derivative complaint names certain current and former officers and directors as defendants, and generally alleges that they breached their fiduciary duties by causing or failing to prevent the securities violations alleged in the securities class action. The Company believes that the claims are without merit and intend to defend vigorously against them, but there can be no assurances as to the outcome.

Employee Benefit Plan

Employee Benefit Plan	6 Months Ended
	Dec. 31, 2024
Employee Benefit Plan
Employee Benefit Plan	11. Employee Benefit Plan On August 1, 2021, the Company began sponsoring an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the “401K Plan”) pursuant to which, all employees meeting eligibility requirements are able to participate. Subject to certain limitations in the Internal Revenue Code, eligible employees are permitted to make contributions to the 401K Plan on a pre-tax salary reduction basis and the Company will match 5% of the first 5% of an employee’s contributions to the 401K Plan. The Company made contributions into the plan of approximately $ 27,500 20,500 62,000 51,400

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation – Interim Financial Information	Basis of Presentation – Interim Financial Information These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2024, was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2024 and 2023 in our Annual Report on Form 10-K filed with the SEC on September 30, 2024 (the “2024 Form 10-K”). A summary of significant accounting policies can also be found in those audited financial statements in the 2024 Form 10-K.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of three months or less.
Investments in U.S. Treasury Bills	Investments in U.S. Treasury Bills Investments in U.S. Treasury Bills with maturities greater than three months, are accounted for as available-for-sale and are recorded at fair value. Realized gains were included in the accompanying condensed statements of operations and comprehensive loss from the settlement of available-for-sale investments during the six months ended December 31, 2023. The Company had no outstanding investment securities with original maturities of greater than three months at the time of purchase as of and during the three and six months ended December 31, 2024.
Concentration of Credit Risk in the Financial Service Industry	Concentration of Credit Risk in the Financial Service Industry As of December 31, 2024, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, if liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.
Fair value measurement of assets and liabilities	Fair value measurement of assets and liabilities We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 - Inputs are unobservable inputs based on our assumptions. The Company’s financial instruments include cash and cash equivalents, accounts payable and the carrying value of the operating lease liabilities and notes payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding and potentially outstanding shares of Common Stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the three and six months ending December 31, 2024 and 2023, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the periods presented. The table below shows the potential shares of common stock, presented based on amounts outstanding at each period end, which were excluded from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: Schedule of dilutive securities were excluded from the computation of diluted loss per share December 31, 2024 December 31, 2023 Number of Shares Number of Shares Stock Options 967,811 471,333 Warrants 9,600,835 777,029 Restricted Stock Units 97,067 68,743 Notes payable conversion option - 71,633 Total 10,665,713 1,388,738
Reverse stock split	Reverse stock split The company effected a 1:10 reverse split of the issued and outstanding shares of its Class A common stock which was approved by the board of directors after the approval obtained from shareholders at a special meeting on July 29, 2024 which became effective on Nasdaq on August 6, 2024, 5 trading days after the shareholders’ approval was obtained. All historical share and earnings per share amounts have been retroactively adjusted to reflect the split.
Grant program	Grant program The Company records expenses related to the DOD Long Covid Program as such expenses are incurred. The reimbursement of such expenses is recognized upon receipt of the reimbursement as a credit against the respective expense account.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (“DISE”), which will require additional disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The new standard will be effective for public companies for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company is currently evaluating the impact of this accounting standard update on its financial statements.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	6 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Schedule of dilutive securities were excluded from the computation of diluted loss per share	Schedule of dilutive securities were excluded from the computation of diluted loss per share December 31, 2024 December 31, 2023 Number of Shares Number of Shares Stock Options 967,811 471,333 Warrants 9,600,835 777,029 Restricted Stock Units 97,067 68,743 Notes payable conversion option - 71,633 Total 10,665,713 1,388,738

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Schedule of intangible assets December 31, 2024 June 30, 2024 Intellectual Property $ 2,293,770 $ 2,293,770 Less: Accumulated Amortization (2,000,740 ) (1,886,052 ) Intellectual Property, Net $ 293,030 $ 407,718
Schedule of future amortization expense	Schedule of future amortization expense Year ending June 30, 2025 (Remaining 6 months) $ 114,689 2026 178,341 $ 293,030

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Schedule of note payable	Schedule of note payable December 31, 2024 June 30, 2024 Current portion of Notes Payable $ - $ 5,000,000 Less: debt financing costs - (11,820 ) Less: unearned discount - (111,212 ) Plus: accretion of Loan Premium - 824,242 Current portion of Notes Payable, net of financing costs, unearned premium and discount $ - $ 5,701,210

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of derivative liabilities at fair value	Schedule of derivative liabilities at fair value Fair Value Measurements at December 31, 2024 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ - $ - $ 7,290 $ 7,290 Derivative liability - Conversion Option - - - - Total derivative liabilities $ - $ - $ 7,290 $ 7,290 Fair Value Measurements at June 30, 2024 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ - $ - $ 3,771 $ 3,771 Derivative liability - Conversion option - - - - Total derivative liabilities $ - $ - $ 3,771 $ 3,771
Fair value, liabilities measured on recurring basis	Fair value, liabilities measured on recurring basis Derivative liabilities - Derivative liability - Balance at June 30, 2024 $ 3,771 $ - Additions to level 3 liabilities - - Change in fair value of level 3 liabilities 3,519 - Transfer in and/or out of Level 3 - - Balance at December 31, 2024 $ 7,290 $ - The following table presents the activity for level 3 liabilities measured at fair value using unobservable inputs for the six months ended December 31, 2023: Derivative liability - Derivative liability - Balance at June 30, 2023 $ 894,280 $ 925,762 Additions to level 3 liabilities - - Change in fair value of level 3 liabilities (771,122 ) (919,214 ) Transfer in and/or out of level 3 - - Balance at December 31, 2023 $ 123,158 $ 6,548
Measured at fair value on a recurring basis	Measured at fair value on a recurring basis Fair Value Measurements at December 31, 2024 Level 1 Level 2 Level 3 Total Cash $ 4,326,075 $ - $ - $ 4,326,075 U.S. Treasury Bills due in 3 months or less at purchase 20,079,442 - - 20,079,442 Total $ 24,405,517 $ - $ - $ 24,405,517 Fair Value Measurements at June 30, 2024 Level 1 Level 2 Level 3 Total Cash $ 12,763,941 $ - $ - $ 12,763,941 U.S. Treasury Bills due in 3 months or less at purchase 11,079,857 - - 11,079,857 Total $ 23,843,798 $ - $ - $ 23,843,798

Equity Transactions (Tables)

Equity Transactions (Tables)	6 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Schedule of summarizes the activity relating to the Company’s stock options	Schedule of summarizes the activity relating to the Company’s stock options Options Weighted-Average Weighted Remaining Aggregate Intrinsic Outstanding at June 30, 2024 518,076 $ 54.11 6.1 $ - Options Granted 490,261 2.40 7.1 - Options Expired (31,736 ) 71.34 - - Options Canceled (8,790 ) 17.01 - - Outstanding at December 31, 2024 967,811 $ 27.69 6.4 $ 32,196 Exercisable at December 31, 2024 409,987 $ 48.46 5.6 $ 10,732
Schedule of assumptions used	Schedule of assumptions used December 31, 2024 December 31, 2023 Expected life of options (in years) 4 5 Expected volatility 93.44% 87.11% Risk free interest rate 4.34% 4.80% Dividend Yield 0% 0%
Schedule of unvested of restricted stock units	Schedule of unvested of restricted stock units Number of Shares Weighted Average Grant Unvested at June 30, 2024 40,291 $ 44.59 Issued 66,900 3.36 Vested (15,291 ) 47.33 Canceled (2,913 ) 36.45 Unvested at December 31, 2024 88,987 $ 13.41
Summary of warrants activity	Summary of warrants activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Life Aggregate Intrinsic Value Outstanding and exercisable at June 30, 2024 1,932,029 $ 14.03 4.0 $ - Granted 10,181,640 1.65 4.8 - Exercised (2,502,967 ) 1.53 - - Expired (9,867 ) 22.50 - - Outstanding and exercisable at December 31, 2024 9,600,835 $ 3.50 4.6 $ 3,322,376
Schedule of warrants outstanding	Schedule of warrants outstanding Number of Warrants Expiring June 30, 2025 271 2026 3,518 2027 36,100 2028 727,273 2029 1,155,000 2030 7,678,673 Total outstanding warrants 9,600,835

Leases (Tables)

Leases (Tables)	6 Months Ended
	Dec. 31, 2024
Leases
Schedule of deferred tax assets	Schedule of deferred tax assets December 31, 2024 June 30, 2024 Assets Operating lease right-of-use asset, net $ 374,303 $ 406,726 Liabilities Current portion of operating lease liability $ 67,111 $ 60,343 Operating lease liability, net of current portion 314,915 349,894 Total operating lease liability $ 382,026 $ 410,237
Schedule of future estimated minimum lease payments under non-cancelable operating leases	Schedule of future estimated minimum lease payments under non-cancelable operating leases Year ending June 30, 2025 (Remaining 6 months) $ 59,805 2026 122,042 2027 126,313 2028 130,734 2029 77,796 Total minimum lease payments 516,690 Less amount representing interest (134,664 ) Present value of future minimum lease payments 382,026 Less current portion of operating lease liability (67,111 ) Operating lease liability, net of current portion $ 314,915
Schedule of weighted average remaining lease term and discount rate	Schedule of weighted average remaining lease term and discount rate December 31, 2024 June 30, 2024 Weighted average remaining lease term (Years) Operating lease 4.1 4.6 Weighted average discount rate Operating lease 15.00 % 15.00 %

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative)	Dec. 31, 2024 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital	$ 23,200,000
Cash and cash equivalent	24,400,000
Stockholders' equity	23,900,000
Accumulated deficit	$ 345,900,000

Significant Accounting Polici_4

Significant Accounting Policies (Details) - shares	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	10,665,713	1,388,738
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	967,811	471,333
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	9,600,835	777,029
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	97,067	68,743
Notespayable Conversion Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		71,633

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intellectual Property	$ 2,293,770	$ 2,293,770
Less: Accumulated Amortization	(2,000,740)	(1,886,052)
Intellectual Property, Net	$ 293,030	$ 407,718

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Year ending June 30, 2025 (Remaining 9 months)	$ 114,689
2026	178,341
Finite lived intangible assets, net	$ 293,030	$ 407,718

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expenses	$ 57,344	$ 57,344	$ 114,688	$ 114,688
Useful life	10 years		10 years

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Dec. 31, 2024	Sep. 25, 2024	Jun. 30, 2024	Jul. 15, 2022
Related Party Transaction [Line Items]
Common stock, shares issued	18,478,307		18,478,307	1,360,800	6,216,398
Deemed dividend	$ 44,424	$ 325,041	$ 369,465
Exercise price				$ 1.53
Selling, General and Administrative Expenses [Member]
Related Party Transaction [Line Items]
Consulting services fee	$ 50,000
Warrants [Member]
Related Party Transaction [Line Items]
Stock price	$ 3.36	$ 1.20	$ 3.36
Remaining term	2 years 9 months 18 days	2 years 10 months 24 days	2 years 9 months 18 days
Risk free rate	3.99%	3.50%
Volatility	94%	93%
Warrants [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Exercise price	$ 1.37	$ 1.53	$ 1.37
Warrants [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Exercise price	$ 1.53	$ 10	$ 1.53
Acuitas Group Holdings, LLC [Member]
Related Party Transaction [Line Items]
Common stock, shares issued						363,636

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Debt Disclosure [Abstract]
Current portion of Notes Payable		$ 5,000,000
Less: debt financing costs		(11,820)
Less: unearned discount		(111,212)
Plus: accretion of Loan Premium		824,242
Current portion of Notes Payable, net of financing costs, unearned premium and discount		$ 5,701,210

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Interest rate			4.25%
Fair value of warrants			$ 1,400,000
Fair value of embedded conversion option			2,200,000
Direct financing cost			390,000
Unamortized premium recognized	$ 850,000		850,000
Interest expense	62,000	$ 682,000	312,000	$ 1,500,000
Interest payment	33,000	429,000	163,000	955,000
Amortization of financing costs	2,000	31,000	12,000	69,000
Unearned discount	22,000	289,000	111,000	645,000
Accretion of loan premium	$ 5,000	$ 67,000	$ 26,000	$ 149,000
Prime Rate [Member]
Debt Instrument [Line Items]
Interest rate			7%

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Dec. 31, 2024	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	$ 7,290	$ 3,771
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	7,290	3,771
Derivative liability - Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	7,290	3,771
Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	7,290	3,771	$ 123,158	$ 894,280
Derivative Liability Conversion Option [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives			$ 6,548	$ 925,762

Fair Value Measurements (Deta_2

Fair Value Measurements (Details 1) - USD ($)	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	$ 3,771
Balance at ending	7,290
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	3,771
Balance at ending	7,290
Derivative liability - Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	3,771
Balance at ending	7,290
Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	3,771	$ 894,280
Additions to level 3 liabilities
Change in in fair value of level 3 liabilities	3,519	(771,122)
Transfer in and/or out of Level 3
Balance at ending	7,290	123,158
Derivative Liability Conversion Option [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning
Balance at ending
Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning		925,762
Additions to level 3 liabilities
Change in in fair value of level 3 liabilities		(919,214)
Transfer in and/or out of Level 3
Balance at ending		$ 6,548

Fair Value Measurements (Deta_3

Fair Value Measurements (Details 2) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 24,405,517	$ 23,843,798
US Treasury Bill Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	20,079,442	11,079,857
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	24,405,517	23,843,798
Fair Value, Inputs, Level 1 [Member] | US Treasury Bill Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	20,079,442	11,079,857
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 2 [Member] | US Treasury Bill Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 3 [Member] | US Treasury Bill Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	4,326,075	12,763,941
Cash [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	4,326,075	12,763,941
Cash [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Cash [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total

Fair Value Measurements (Deta_4

Fair Value Measurements (Details Narrative) - USD ($)	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants	$ 7,290		$ 3,771
Fair value of the derivative liabilities	3,519	$ 1,700,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants	7,290		3,771
Derivative liability - Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants	7,290		3,771
Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants	$ 7,290	$ 123,158	$ 3,771	$ 894,280
Share Price	$ 2
Exercise Price	$ 58.20
Term	1 year 10 months 24 days
Risk Free Interest Rate	4.20%
Volatility Rate	95%

Equity Transactions (Details)

Equity Transactions (Details) - Stock Options [Member]	6 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Offsetting Assets [Line Items]
Options outstanding at beginning | shares	518,076
Weighted average exercise price, options outstanding at beginning | $ / shares	$ 54.11
Weighted remaining average contractual term, beginning	6 years 1 month 6 days
Aggregate intrinsic value, outstanding at beginning | $
Options granted | shares	490,261
Weighted average exercise price, options granted | $ / shares	$ 2.40
Weighted remaining average contractual term, options granted	7 years 1 month 6 days
Options expired | shares	(31,736)
Weighted average exercise price, Options expired | $ / shares	$ 71.34
Options Canceled | shares	(8,790)
Weighted average exercise price, Options Canceled | $ / shares	$ 17.01
Options outstanding at ending | shares	967,811
Weighted average exercise price, options outstanding at ending | $ / shares	$ 27.69
Weighted remaining average contractual term, ending	6 years 4 months 24 days
Aggregate intrinsic value, outstanding at ending | $	$ 32,196
Options exercisable | shares	409,987
Weighted average exercise price, options exercisable | $ / shares	$ 48.46
Weighted average remaining contractual term, options exercisable	5 years 7 months 6 days
Aggregate intrinsic value. options exercisable | $	$ 10,732

Equity Transactions (Details 1)

Equity Transactions (Details 1) - Stock Options [Member]	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Offsetting Assets [Line Items]
Expected life of options (in years)	4 years	5 years
Expected volatility	93.44%	87.11%
Risk free interest rate	4.34%	4.80%
Dividend Yield	0%	0%

Equity Transactions (Details 2)

Equity Transactions (Details 2)	6 Months Ended
	Dec. 31, 2024 $ / shares shares
Equity [Abstract]
Number of shares unvested at beginning | shares	40,291
Weighted average grant date fair value per share unvested at beginning | $ / shares	$ 44.59
Number of shares, issued | shares	66,900
Weighted average grant date fair value per share, issued | $ / shares	$ 3.36
Number of shares, vested | shares	(15,291)
Weighted average grant date fair value per share, vested | $ / shares	$ 47.33
Number of shares, canceled | shares	(2,913)
Weighted average grant date fair value per share, canceled | $ / shares	$ 36.45
Number of shares unvested at ending | shares	88,987
Weighted average grant date fair value per share unvested at ending | $ / shares	$ 13.41

Equity Transactions (Details 3)

Equity Transactions (Details 3) - Warrant [Member]	6 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares, beginning | shares	1,932,029
Weighted average exercise price, beginning | $ / shares	$ 14.03
Weighted average remaining life (Years)	4 years
Aggregate intrinsic value, outstanding at beginning | $
Number of shares, granted | shares	10,181,640
Weighted average exercise price, granted | $ / shares	$ 1.65
Weighted average remaining life (Years), granted	4 years 9 months 18 days
Number of shares, exercised | shares	(2,502,967)
Weighted average exercise price, exercised | $ / shares	$ 1.53
Number of shares, expired | shares	(9,867)
Weighted average exercise price, expired | $ / shares	$ 22.50
Number of shares, ending | shares	9,600,835
Weighted average exercise price, ending | $ / shares	$ 3.50
Weighted average remaining life (Years)	4 years 7 months 6 days
Aggregate intrinsic value, outstanding at ending | $	$ 3,322,376

Equity Transactions (Details 4)

Equity Transactions (Details 4)	Dec. 31, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total outstanding warrants	9,600,835
Year 2025 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total outstanding warrants	271
Year 2026 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total outstanding warrants	3,518
Year 2027 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total outstanding warrants	36,100
Year 2028 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total outstanding warrants	727,273
Year 2029 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total outstanding warrants	1,155,000
Year 2030 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total outstanding warrants	7,678,673

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)		1 Months Ended					3 Months Ended		6 Months Ended
	Aug. 12, 2023	Dec. 20, 2024	Nov. 23, 2024	Nov. 20, 2024	Oct. 31, 2024	Sep. 25, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
Class of Stock [Line Items]
Common stock shares						1,360,800	18,478,307		18,478,307		6,216,398
Common stock per value						$ 0.0001	$ 0.0001		$ 0.0001		$ 0.0001
Class of warrant or right, exercise price of warrants or rights						$ 1.53
Proceeds from offering						$ 3,000,000
Offering shares					8,256,000
Offering price per share					$ 0.0001
Common stock issued							4,214
Stock-based compensation expense									$ 504,226	$ 1,427,728
RSUs vested									15,291
Stock Options [Member]
Class of Stock [Line Items]
Stock-based compensation expense							$ 385,000	$ 620,000	$ 504,000	1,400,000
Stock Options [Member] | Employee [Member]
Class of Stock [Line Items]
Number of stock options purchased		208,902
Exercise price		$ 1.90
Fair value of stock options		$ 1.43
Stock Options [Member] | Director [Member]
Class of Stock [Line Items]
Number of stock options purchased		113,055
Exercise price		$ 1.90
Fair value of stock options		$ 1.20
Vendor [Member]
Class of Stock [Line Items]
Stock issued during period for service	15,000
Share price	$ 2.23
Stock-based compensation expense	$ 33,450
October Common Warrants [Member]
Class of Stock [Line Items]
Proceeds from offering					$ 15,900,000
Proceeds from issuance of warrants					$ 7,110,000
Warrant, exercise price, decrease					$ 1.37
Warrant, exercise price, increase					$ 2.12
Agent fees and offering expenses					$ 2,500,000
October Common Warrants [Member] | Minimum [Member]
Class of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights					$ 1.50
October Common Warrants [Member] | Maximum [Member]
Class of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights					2.83
October Placement Agents Warrants [Member]
Class of Stock [Line Items]
Warrant, exercise price, decrease					1.88
Warrant, exercise price, increase					$ 3.54
September 2024 Offering [Member]
Class of Stock [Line Items]
Proceeds from offering							$ 2,900,000
Warrant, exercise price, increase							$ 1.53
Warrants exercised							1,896,300
Prefunded Warrants [Member]
Class of Stock [Line Items]
Warrants exercised							335,000
September Placement Agents Warrants [Member]
Class of Stock [Line Items]
Warrants exercised							6,667
Placement Agents Warrants [Member]
Class of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights						$ 125
Warrant issued						98,040
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Stock-based compensation expense							$ 266,000	$ 303,000	$ 567,000	$ 684,000
RSUs vested			8,080						3,410
Restricted Stock Units (RSUs) [Member] | Consultant [Member]
Class of Stock [Line Items]
RSUs vested							397
Restricted Stock Units (RSUs) [Member] | Two Directors [Member] | N 2019 Omnibus Incentive Equity Plan [Member]
Class of Stock [Line Items]
Rsu granted				66,900
Rsu granted, grant date fair value				$ 3.36
Restricted Stock Units (RSUs) [Member] | Four Director [Member] | N 2019 Omnibus Incentive Equity Plan [Member]
Class of Stock [Line Items]
Rsu granted				168,300
Rsu granted, grant date fair value				$ 3.36
Common Class A [Member] | Sales Agreement [Member]
Class of Stock [Line Items]
Issuance of common stock for cash, shares								290,090	2,143	333,310
Issuance of common stock for cash								$ 7,400,000	$ 6,400	$ 9,300,000
Commissions percentage								3%	3%	3%
Issuance costs								$ 258,000	$ 200	$ 377,000
Prefunded Warrants [Member]
Class of Stock [Line Items]
Purchase of shares						600,000
Common Warrants [Member]
Class of Stock [Line Items]
Common stock per value						$ 1.53
Purchase of shares						1,960,800

Leases (Details)

Leases (Details) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Leases
Operating lease right-of-use asset, net	$ 374,303	$ 406,726
Current portion of operating lease liability	67,111	60,343
Operating lease liability, net of current portion	314,915	349,894
Total operating lease liability	$ 382,026	$ 410,237

Leases (Details 1)

Leases (Details 1) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Leases
Year ending June 30, 2025 (Remaining 6 months)	$ 59,805
2026	122,042
2027	126,313
2028	130,734
2029	77,796
Total minimum lease payments	516,690
Less amount representing interest	(134,664)
Present value of future minimum lease payments	382,026	$ 410,237
Less current portion of operating lease liability	(67,111)	(60,343)
Operating lease liability, net of current portion	$ 314,915	$ 349,894

Leases (Details 2)

Leases (Details 2)	Dec. 31, 2024	Jun. 30, 2024
Leases
Weighted average remaining lease term (Years) Operating leases	4 years 1 month 6 days	4 years 7 months 6 days
Weighted average discount rate Operating leases	15%	15%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 29, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Oct. 02, 2023
Operating lease cost		$ 32,000	$ 13,000	$ 63,000	$ 26,000
Cash paid for amounts included in measurement of operating lease liabilities				58,110	$ 25,800
Office Leases [Member]
Annual rent				$ 2,200
Lease term	60 months					1 year
Monthly rent	$ 9,685

Employee Benefit Plan (Details

Employee Benefit Plan (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Employee Benefit Plan
Employee's contributions	$ 27,500	$ 20,500	$ 62,000	$ 51,400